Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

BACKGROUND: Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis. Dasatinib inhibits tyrosine kinases, including Src kinases. Data suggests that dasatinib kinase inhibition leads to antitumour activity, affects osteoclasts, and has synergy with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Araujo, John C, Trudel, Géralyn C, Saad, Fred, Armstrong, Andrew J, Yu, Evan Y, Bellmunt, Joaquim, Wilding, George, McCaffrey, John, Serrano, Sergio V, Matveev, Vsevolod B, Efstathiou, Eleni, Oudard, Stephane, Morris, Michael J, Sizer, Bruce, Goebell, Peter J, Heidenreich, Axel, de Bono, Johann S, Begbie, Stephen, Hong, Jun H, Richardet, Eduardo, Gallardo, Enrique, Paliwal, Prashni, Durham, Susan, Cheng, Shinta, Logothetis, Christopher J
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478530/
https://ncbi.nlm.nih.gov/pubmed/24211163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70479-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados